Effect of biological therapy on levels of atheroprotective antibodies against phosphorylcholine and apolipoproteins in rheumatoid arthritis – a one year study

Clinical and Experimental Rheumatology

Sofia Ajeganova¹  Johan Frostegård¹  Ulf de Faire¹  Ingiäld Hafström¹  Roland Fiskesund¹ 

关键词: Rheumatoid arthritis;    antibodies against phosphorylcholine;    apolipoprotein A1;    biological therapy;    remission;    rituximab;    tumor necrosis factor inhibitors;    Rituximab;    rheumatoid arthritis;   

DOI  :  

学科分类：医学（综合）

来源: Pacini Editore SpA

【 摘 要 】

OBJECTIVES: To examine how treatment of rheumatoid arthritis (RA) with anti-tumour necrosis factor alpha antagonists (anti-TNF) and B-cell targeting rituximab influences novel markers of atherosclerosis and inflammation, such as atheroprotective natural IgM antibodies against phosphorylcholine (anti-PC), oxidised low-density lipoprotein (oxLDL) and apolipoproteins. METHODS: In a prospective study 215 patients with RA were enrolled of whom 85.6% were seropositive, aged 57.9±12.4 years, with mean disease duration 8.5 (5–15) years. 162 patients were treated with anti-TNF and 53 with rituximab for one year. The patients were assessed and blood sampled at 0, 3, 6 and 12 months. IgM anti-PC and oxLDL were determined by ELISA and apolipoproteins by immunoturbidimetry. RESULTS: IgM anti-PC increased by 26% during anti-TNF treatment, p

【 授权许可】

Unknown